Development of recalcitrant cutaneous eruptions in patients with relapsed/refractory Hodgkin's lymphoma undergoing treatment with camidanlumab tesirine

J Eur Acad Dermatol Venereol. 2023 Jul;37(7):e890-e893. doi: 10.1111/jdv.18983. Epub 2023 Mar 1.

Authors

Sonia Himed^{1

2}, Catherine Chung^{2

3}, Brittany Dulmage², Samantha Jaglowski⁴, David Bond⁴, Kami Maddocks⁴, Benjamin H Kaffenberger²

Affiliations

¹ University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
² Division of Dermatology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
³ Department of Internal Medicine Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
⁴ Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

PMID: 36800311
DOI: 10.1111/jdv.18983

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents* / therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Hodgkin Disease* / drug therapy
Humans
Immunoconjugates*
Neoplasm Recurrence, Local / drug therapy
Recurrence
Treatment Outcome

Substances

Antineoplastic Agents
Immunoconjugates